Extending Benefit by Targeting Resistant Lesions in mCRPC
Official title: Project 3: Extending Clinical Benefit by Selective Treatment of Resistant Lesions in mCRPC
Funded at University of Wisconsin-Madison · NIH-11398992 · Data updated 2026-11-12
A cancer center plans to identify on-treatment resistant spots in men with metastatic castration-resistant prostate cancer and then use targeted local therapy to those spots while systemic treatment continues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $364,483 |
| NIH project number | 5P50CA269011-04 |
| Project ID | NIH-11398992 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with metastatic castration-resistant prostate cancer who are receiving second-generation androgen-signaling inhibitors and have progression on some lesions but continued response on others.
✕Less likely to help
Patients whose disease is widespread without responding lesions or who cannot tolerate local therapies may not benefit.
What this research studies
This project uses advanced imaging analytics to find resistant tumor sites in men with mCRPC who are still benefiting from most therapies. If resistant lesions are found, the team will model and test how targeted local treatments like SBRT could extend overall clinical benefit. The study will analyze PET/CT scans to pinpoint resistant lesions early and simulate how removing them might reduce total tumor burden. A prospective feasibility component will assess whether selectively treating these lesions is doable in real patient care.
Why it matters
Potential benefit: If successful, patients could experience longer benefit from current systemic therapy by adding precision local treatment to resistant lesions.
How similar studies have gone: Previous work suggests lesion-level heterogeneity; this study extends that approach with a novel imaging analytics method to guide targeted treatment.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Liu, Glenn — University of Wisconsin-Madison
- Study coordinator: Liu, Glenn
Related research
Other NIH-funded projects on the same topics.
-
Dual Targeting of B7-H3 in metastatic prostate cancer
A Johns Hopkins team is testing two targeted therapies against B7-H3 to help people with metastatic castration-resistant prostate cancer feel better and show tumor responses.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer
A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.
-
Multidimensional approach to boost PSMA-RPT success in advanced prostate cancer
A cancer research grant aims to better understand why PSMA-targeted radiopharmaceutical therapy works sometimes but not always for advanced prostate cancer, with the goal of making treatments more effective for patients who need them.
-
Targeted radiation approach for prostate cancer without continuous castration
A study testing a targeted radiation plan for men with metastatic castration-resistant prostate cancer to improve outcomes and quality of life by avoiding continuous castration for those receiving PSMA-directed therapy.
-
Liquid biopsy test to guide HER2-targeted therapy for advanced prostate cancer
A new liquid biopsy test using blood markers to pick and guide HER2-directed therapy for men with advanced, treatment-resistant prostate cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.